Drug Profile
Research programme: tobacco plant-based biosimilars - Cellectis/Medicago
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medicago
- Class Plant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Canada
- 18 Sep 2013 Medicago has been acquired by Mitsubishi Tanabe Pharma Corporation
- 04 Oct 2012 Early research in Undefined indication in Canada (unspecified route)